Emerald Mutual Fund Advisers Trust’s Pacira BioSciences PCRX Stock Holding History

Emerald Mutual Fund Advisers Trust’s Portfolio PCRX Stock Details PCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-176,675	Closed	-$6.82M	–	258
2022 Q4	$6.82M	Sell	176,675 -226,439	-56%	-$11M	0.42%	89
2022 Q3	$21.4M	Buy	403,114 +100,636	+33%	+$5.6M	1.36%	15
2022 Q2	$17.6M	Buy	302,478 +49,651	+20%	+$3.25M	1.02%	31
2022 Q1	$19.3M	Buy	+252,827	New	+$16.9M	0.85%	44

Other funds holding PCRX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

FCM

Frontier Capital Management Boston, Massachusetts $9.73B AUM 55.65% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

SIMG

Stephens Investment Management Group Houston, Texas $9.33B AUM 56.1% 1-Year Est. Return

Emerald Mutual Fund Advisers Trust's PCRX Position: Q1 2023 in Review

Emerald Mutual Fund Advisers Trust sold out of Pacira BioSciences (PCRX) in Q1 2023, closing a stake of 176,675 shares — an estimated $6.82M sold.

Emerald Mutual Fund Advisers Trust first reported a position in PCRX in Q1 2022 and held it in 4 quarters. The position peaked at $21.4M in Q3 2022. 267 funds tracked by Wall St. Rank hold PCRX as of Q1 2023.

Emerald Mutual Fund Advisers Trust reported no remaining Pacira BioSciences position as of Q1 2023 after selling out during the quarter.
Emerald Mutual Fund Advisers Trust sold 176,675 Pacira BioSciences shares in Q1 2023, an estimated $6.82M.
Emerald Mutual Fund Advisers Trust first reported a position in Pacira BioSciences in Q1 2022 and held it in 4 quarters.
Emerald Mutual Fund Advisers Trust's Pacira BioSciences position peaked at $21.4M in Q3 2022.
267 funds tracked by Wall St. Rank held Pacira BioSciences as of Q1 2023.

Based on Emerald Mutual Fund Advisers Trust's 13F filing for Q1 2023, filed 4 May 2023.